Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused
on generating data-driven insights to diagnose, understand,
and treat rare diseases, today announced the global release
of CentoCloud, a SaaS platform enabling decentralized
analysis, interpretation, and reporting of genomic variants
linked to rare diseases.
Generating medical reports of diagnostic analyses is resource
intensive – requiring an extensive amount of bioinformatic
expertise, a sizeable databank of patient samples, and a
streamlined recording system. Furthermore, as a trend, an
increasing number of laboratories around the world are responding
to regional requirements for increasing the amount of genetic
sequencing being performed locally. CentoCloud, powered by proven
bioinformatic pipelines and the world’s largest Bio/Databank of its
kind, helps overcome these obstacles to make rare disease
diagnostics accessible around the world.
By providing a decentralized workflow, this fully digital
solution aggregates Next Generation Sequencing (NGS) data from
laboratories into the cloud, where automated, curated,
bioinformatic analysis and AI-based genomic variant prioritization
and classification generate high quality reporting of the utmost
value. Additionally, the insights generated from consented data via
CentoCloud will augment the Bio/Databank and may contribute to the
discovery and development of novel therapeutics to treat rare
diseases in the future.
“At CENTOGENE, we are committed to continuing to expand our
footprint to enable access to genetic testing for rare
diseases anywhere in the world,” said Dr. Maximilian Schmid,
CENTOGENE’s Chief Commercial Officer - Diagnostics. “Taking
CentoCloud from a proof-of-concept to a commercialized service,
labs around the world now have direct access to straightforward
implementation of NGS and can deliver timely results to combat rare
diseases, no matter where they are found.”
CentoCloud – The End-to-End Decentralized Diagnostic
Solution The digital bioinformatics solution offers
several key features that advance rare disease patient care:
Accessibility
- CentoCloud has been designed to complement the large existing
base of state-of-the-art Illumina sequencing analyzer technology
products around the world. In addition, earlier this year CENTOGENE
announced a collaboration with Twist Bioscience to leverage their
expertise in genetic kit development. Laboratories taking advantage
of the CentoCloud SaaS platform benefit from higher diagnostic
yields and a faster time to diagnosis at lower overall costs
Automation
- The automated bioinformatics pipeline analyzes NGS data based
on CENTOGENE's validated testing products, annotated with data from
the Company’s proprietary rare disease-centric Bio/Databank
Accuracy
- Drawing on more than 15 years of rare disease diagnostic
experience and AI-supported clinical interpretation and medical
reporting, CentoCloud facilitates the same high quality and
diagnostic accuracy as CENTOGENE offers in its own certified
state-of-the-art labs
For further information about CentoCloud, visit:
https://www.centogene.com/diagnostics/centocloud-bioinformatics-solution.html
This cloud-based SaaS solution represents another significant
step forward for CENTOGENE’s mission to increase its diagnostic
footprint and enable the cure of 100 rare diseases within the next
10 years. To learn more, visit:
https://www.centogene.com/virtual-investor-event
About CENTOGENE
CENTOGENE engages in diagnosis and research around rare diseases
transforming real-world clinical, genetic, and multiomic data to
diagnose, understand, and treat rare diseases. Our goal is to bring
rationality to treatment decisions and to accelerate the
development of new orphan drugs by using our extensive rare disease
knowledge and data. CENTOGENE has developed a global proprietary
rare disease platform based on our real-world data repository of
over 600,000 patients representing over 120 different
countries.
The Company’s platform includes epidemiologic, phenotypic, and
genetic data that reflects a global population, as well as a
biobank of patients’ blood samples and cell cultures. CENTOGENE
believes this represents the only platform focused on comprehensive
analysis of multi-level data to improve the understanding of rare
hereditary diseases. It allows for better identification and
stratification of patients and their underlying diseases to enable
and accelerate discovery, development, and access to orphan drugs.
As of December 31, 2020, the Company collaborated with over 30
pharmaceutical partners.
Follow us on LinkedIn
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative worldwide economic conditions and ongoing instability and
volatility in the worldwide financial markets, the effects of the
COVID-19 pandemic on our business and results of operations,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, our reliance on third parties and collaboration
partners, including our ability to manage growth and enter into new
client relationships, our dependency on the rare disease industry,
our ability to manage international expansion, our reliance on key
personnel, our reliance on intellectual property protection,
fluctuations of our operating results due to the effect of exchange
rates, our ability to streamline cash usage, our requirement for
additional financing and our ability to continue as a going
concern, or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on April 15, 2021,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Media
Contact: CENTOGENE Ben
Legg Corporate CommunicationsPress@centogene.com
Lennart StreibelInvestor
RelationsInvestor.Relations@centogene.comStern
IR Brendan Payne+1 (212) 698
8695Brendan.Payne@sternir.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Apr 2023 to Apr 2024